DUN61488 | CAS#1807861-48-8 | GPR132 Agonist

DUN61488
new

featured

WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 207184

CAS#: 1807861-48-8

Description: DUN61488, also known as 2,4,6,7,8,9-Hexahydro-7-(phenylmethyl)-4-[[4-(trifluoromethyl)phenyl]methyl]imidazo[1,2-a]pyrido[3,4-e]pyrimidin-5(1H)-one is a chemical reagent for research use. It has CAS#1807861-48-8. According to MedKoo Chemical Nomenclature ((see web page: https://www.medkoo.com/page/naming)., this chemical can be named as DUN61488.

Chemical Structure

DUN61488

CAS# 1807861-48-8

Instruction

Theoretical Analysis

MedKoo Cat#: 207184
Name: DUN61488
CAS#: 1807861-48-8
Chemical Formula: C24H23F3N4O
Exact Mass: 440.18
Molecular Weight: 440.470
Elemental Analysis: C, 65.44; H, 5.26; F, 12.94; N, 12.72; O, 3.63

Price and Availability

Size	Price	Availability
10mg	USD 150	Ready to ship
25mg	USD 250	Ready to ship
50mg	USD 450	Ready to ship
100mg	USD 750	Ready to ship
200mg	USD 1350	Ready to ship
Bulk inquiry Welcome, Customer: Please do not inquire quote if your intended use is for a patient since our products are for research use and for chemical synthesis use, not for human use . For in-stock products, we listed price in the web page. You may inquire prices for which sizes were not listed. If no price is listed, this means the product is not in stock at the moment, which may be available via custom synthesis. For cost-effective reason, minimum order of 1g is requested (typically very expensive). The lead time is usually 2-4 months. Quote of less than 1g will not be provided. MedKoo may not offer quote for below reasons: (1) current available synthetic method appears to be extremely expensive which is obviously not affordable to most customers; (2) Key raw material to make the product is temporally not available; (3) DEA controlled substances; (4) the product is under patent protection in customer’s country.

Synonym: DUN61488; DUN-61488; DUN 61488;

IUPAC/Chemical Name: 2,4,6,7,8,9-Hexahydro-7-(phenylmethyl)-4-[[4-(trifluoromethyl)phenyl]methyl]imidazo[1,2-a]pyrido[3,4-e]pyrimidin-5(1H)-one

InChi Key: DFULPGUTXZTYKA-UHFFFAOYSA-N

InChi Code: InChI=1S/C24H23F3N4O/c25-24(26,27)19-8-6-18(7-9-19)15-31-22(32)20-16-29(14-17-4-2-1-3-5-17)12-10-21(20)30-13-11-28-23(30)31/h1-9H,10-16H2

SMILES Code: O=C1N(CC2=CC=C(C(F)(F)F)C=C2)C3=NCCN3C4=C1CN(CC5=CC=CC=C5)CC4

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO

Shelf Life: >2 years if stored properly

Drug Formulation: To be determined

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

More Info:

QC Data:

View QC data: current batch, Lot#S22S02C21

Safety Data Sheet (SDS):

View Safety Data Sheet (SDS)

Instruction:

View handling instruction

Biological target:	ONC212, a fluorinated-ONC201 analogue, is a promising anti-cancer agent and also a selective agonist of GPR132.
In vitro activity:	ONC‐212 induced a significant (P < .05) accumulation of cells from both the OSU‐CLL and OSU‐CLL‐TP53ko lines in G0/G1, with a concomitant decrease in the proportion of cells in G2/M at each of the three time points (P < .05; Figure 2A). In the TP53ko cells, a significant (P < .05) increase in the proportion of cells in S phase was also observed with ONC‐212 treatment at each time point. Reference: EJHaem. 2021 Jan 14;2(1):81-93. https://pubmed.ncbi.nlm.nih.gov/35846080/
In vivo activity:	Immunohistochemical analyses of Ki67 and caspase-3 demonstrated that ONC212 reduced tumor-cell proliferation and induced apoptosis in UACC-903 and MALME xenografts to a greater extent than ONC201 (Fig. 7d, Fig. S4c). Reference: Cell Cycle. 2017 Oct 2;16(19):1790-1799. https://pubmed.ncbi.nlm.nih.gov/28489985/

Solubility Data

	Solvent	Max Conc. mg/mL	Max Conc. mM
Solubility
	DMF	1.0	2.27
	DMSO	25.5	57.89
	DMSO:PBS (pH 7.2) (1:3)	0.3	0.57

Preparing Stock Solutions

The following data is based on the product molecular weight 440.47 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

Formulation protocol:	1. Ferrarini I, Louie A, Zhou L, El-Deiry WS. ONC212 is a Novel Mitocan Acting Synergistically with Glycolysis Inhibition in Pancreatic Cancer. Mol Cancer Ther. 2021 Sep;20(9):1572-1583. doi: 10.1158/1535-7163.MCT-20-0962. Epub 2021 Jun 17. PMID: 34224362; PMCID: PMC8419089. 2. Fatima N, Shen Y, Crassini K, Iwanowicz EJ, Lang H, Karanewsky DS, Christopherson RI, Mulligan SP, Best OG. The ClpP activator ONC-212 (TR-31) inhibits BCL2 and B-cell receptor signaling in CLL. EJHaem. 2021 Jan 14;2(1):81-93. doi: 10.1002/jha2.160. PMID: 35846080; PMCID: PMC9175891. 3. Wagner J, Kline CL, Ralff MD, Lev A, Lulla A, Zhou L, Olson GL, Nallaganchu BR, Benes CH, Allen JE, Prabhu VV, Stogniew M, Oster W, El-Deiry WS. Preclinical evaluation of the imipridone family, analogs of clinical stage anti-cancer small molecule ONC201, reveals potent anti-cancer effects of ONC212. Cell Cycle. 2017 Oct 2;16(19):1790-1799. doi: 10.1080/15384101.2017.1325046. Epub 2017 May 10. PMID: 28489985; PMCID: PMC5628644. 4. Lev A, Lulla AR, Wagner J, Ralff MD, Kiehl JB, Zhou Y, Benes CH, Prabhu VV, Oster W, Astsaturov I, Dicker DT, El-Deiry WS. Anti-pancreatic cancer activity of ONC212 involves the unfolded protein response (UPR) and is reduced by IGF1-R and GRP78/BIP. Oncotarget. 2017 Sep 12;8(47):81776-81793. doi: 10.18632/oncotarget.20819. PMID: 29137221; PMCID: PMC5669847.
In vitro protocol:	1. Ferrarini I, Louie A, Zhou L, El-Deiry WS. ONC212 is a Novel Mitocan Acting Synergistically with Glycolysis Inhibition in Pancreatic Cancer. Mol Cancer Ther. 2021 Sep;20(9):1572-1583. doi: 10.1158/1535-7163.MCT-20-0962. Epub 2021 Jun 17. PMID: 34224362; PMCID: PMC8419089. 2. Fatima N, Shen Y, Crassini K, Iwanowicz EJ, Lang H, Karanewsky DS, Christopherson RI, Mulligan SP, Best OG. The ClpP activator ONC-212 (TR-31) inhibits BCL2 and B-cell receptor signaling in CLL. EJHaem. 2021 Jan 14;2(1):81-93. doi: 10.1002/jha2.160. PMID: 35846080; PMCID: PMC9175891.
In vivo protocol:	1. Wagner J, Kline CL, Ralff MD, Lev A, Lulla A, Zhou L, Olson GL, Nallaganchu BR, Benes CH, Allen JE, Prabhu VV, Stogniew M, Oster W, El-Deiry WS. Preclinical evaluation of the imipridone family, analogs of clinical stage anti-cancer small molecule ONC201, reveals potent anti-cancer effects of ONC212. Cell Cycle. 2017 Oct 2;16(19):1790-1799. doi: 10.1080/15384101.2017.1325046. Epub 2017 May 10. PMID: 28489985; PMCID: PMC5628644. 2. Lev A, Lulla AR, Wagner J, Ralff MD, Kiehl JB, Zhou Y, Benes CH, Prabhu VV, Oster W, Astsaturov I, Dicker DT, El-Deiry WS. Anti-pancreatic cancer activity of ONC212 involves the unfolded protein response (UPR) and is reduced by IGF1-R and GRP78/BIP. Oncotarget. 2017 Sep 12;8(47):81776-81793. doi: 10.18632/oncotarget.20819. PMID: 29137221; PMCID: PMC5669847.

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.

Mass

Concentration

Volume

M. Wt* g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

Volume (to add to vial)

Mass (in vial)

Desired Reconstitution Concentration

Dilution Calculator

Calculate the dilution required to prepare a stock solution.

Concentration 1

Volume 1

Concentration 2

Volume 2

Your view history

DUN61488 new featured